StockMarketWire.com - Hemogenyx Pharmaceuticals said Friday its subsidiary Immugenyx had entered into a collaboration agreement with Orgenesis to develop the company's advanced hematopoietic chimeras.
Immugenyx said it would collaborate with Orgenesis on the further development and commercialization of the company's advanced hematopoietic chimeras, a new type of humanised mouse with a functional human immune system for disease modelling and the development of drugs and cell therapies.
'As a company committed to the discovery and development of novel therapeutic products for patients suffering from blood and severe autoimmune diseases, we are pleased to partner with Orgenesis, a premier service provider in the regenerative medicine industry and a pioneer in cell reprogramming. The commercial collaboration, license agreement and investment is an additional confirmation of the uniqueness and value of Immugenyx' AHC platform.' said Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx.
At 9:47am: [LON:HEMO] Hemogenyx Pharmaceuticals Plc share price was +0.2p at 2.95p
Story provided by StockMarketWire.com
Shares Magazine

Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events

Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.